Home / News / India News / Article /
India's drugs regulator gives nod to phase-3 clinical trial of Covid vaccine Covovax
Updated On: 23 March, 2022 06:03 PM IST | New Delhi | PTI
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28 last year and for inoculating the beneficiaries in the 12-17 years age group, subject to certain conditions, on March 9
Representative image. Pic/ istock
The Drugs Controller General of India (DCGI) granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said.
The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose in adults who have been fully vaccinated with either Covaxin or Covishield at least three months ago.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT